A Xarelto patient is fighting back against the reversal of a $28 million verdict against drug maker Johnson & Johnson (subsidiaries Bayer and Janssen), which she initially won for an alleged failure to warn against the heightened risk of internal bleeding. The verdict in Hartman et al v. Janssen Pharmaceuticals…
Drug companies are big multinational corporations for the most part, and as such report their profits and losses to Wall Street each quarter. That means these firms are very concerned about making money for their shareholders and their executives. There is no question many medicines they make save a lot of lives.…
According to a recent news article from the Cook County Record, a woman has just filed a lawsuit against Bayer and Johnson & Johnson/Janssen Pharmaceuticals, who are the makers and U.S. marketing partners of the New Oral Anticoagulant (NOAC) Xarelto. This lawsuit alleges that, after taking Xarelto, she suffered serious…
According to a recent report from WebMD News, a recent study, which asserted both Xarelto and Pradaxa were superior to Warfarin, found that Xarelto poses a higher risk of serious internal bleeding disorders than its competitor, Pradaxa. The drugs at issue are part of a new class of anticoagulants known…
According to a recent news article from the Louisiana Record, the surviving daughter of a man from Ohio claims that her father died as a result of complications due to taking Xarelto. The complaint was filed on April 8, 2016 in a United States District Court. Plaintiff filed the suit…
Xarelto, Eliquis, Pradaxa, and the newly-marketed Savaysa are all members of a class of drugs known as New Oral Anticoagulants (NOACs). They are all advertised as a safer and easier to use alternative to Warfarin (Coumadin), which has been the long-standing drug prescribed to patients who suffer from an irregular…